Adverum Biotechnologies (NASDAQ:ADVM) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.
Insider & Institutional Ownership
97.4% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 22.9% of Autolus Therapeutics shares are owned by institutional investors. 12.4% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Adverum Biotechnologies and Autolus Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Adverum Biotechnologies | $250,000.00 | 4,349.97 | $-64,490,000.00 | ($1.01) | -11.01 |
| Autolus Therapeutics | $2.91 million | 111.14 | $-123,850,000.00 | ($2.88) | -2.15 |
Adverum Biotechnologies has higher earnings, but lower revenue than Autolus Therapeutics. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Adverum Biotechnologies and Autolus Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Adverum Biotechnologies | N/A | -32.23% | -28.02% |
| Autolus Therapeutics | -8,652.90% | -54.01% | -44.19% |
Volatility and Risk
Adverum Biotechnologies has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Adverum Biotechnologies and Autolus Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Adverum Biotechnologies | 0 | 2 | 8 | 0 | 2.80 |
| Autolus Therapeutics | 0 | 1 | 7 | 0 | 2.88 |
Adverum Biotechnologies presently has a consensus target price of $23.50, indicating a potential upside of 111.33%. Autolus Therapeutics has a consensus target price of $21.7143, indicating a potential upside of 250.80%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Adverum Biotechnologies.
Summary
Adverum Biotechnologies beats Autolus Therapeutics on 9 of the 14 factors compared between the two stocks.
